Armillarisin A exhibits significant antiviral activity, particularly against hepatitis B virus (HBV). It effectively suppresses HBV DNA replication and reduces the expression of viral antigens in vitro, making it a promising candidate for the development of anti-HBV therapeutics. Its mechanism involves interference with viral replication pathways, potentially through modulation of host cell factors involved in viral gene expression. Due to its natural origin and targeted action, Armillarisin A is being studied for use in novel antiviral formulations, especially for chronic hepatitis B treatment. Additionally, it shows low cytotoxicity in host cells, which supports its potential for safe therapeutic application.